NEW YORK (GenomeWeb News) – Sigma Life Science has reached a deal to license its CompoZr Zinc Finger Nuclease technology to Horizon Discovery on a non-exclusive basis, Sigma-Aldrich announced today.

Under the terms of the deal, Horizon will use the technology for the commercial development of cell-based products and to provide commercial gene editing services. Additional terms were not disclosed.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.